MS-DRG 791

Principal Diagnosis - Pdx

• S72.391A Other fracture of shaft of right femur, initial encounter for closed fracture
• S72.391B Other fracture of shaft of right femur, initial encounter for open fracture type I or II
• S72.391C Other fracture of shaft of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC
• S72.392A Other fracture of shaft of left femur, initial encounter for closed fracture
• S72.392B Other fracture of shaft of left femur, initial encounter for open fracture type I or II
• S72.392C Other fracture of shaft of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC
• S72.399A Other fracture of shaft of unspecified femur, initial encounter for closed fracture
• S72.399B Other fracture of shaft of unspecified femur, initial encounter for open fracture type I or II
• S72.399C Other fracture of shaft of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC
• S72.8X1A Other fracture of right femur, initial encounter for closed fracture
• S72.8X1B Other fracture of right femur, initial encounter for open fracture type I or II
• S72.8X1C Other fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC
• S72.8X2A Other fracture of left femur, initial encounter for closed fracture
• S72.8X2B Other fracture of left femur, initial encounter for open fracture type I or II
• S72.8X2C Other fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC
• S72.8X9A Other fracture of unspecified femur, initial encounter for closed fracture
• S72.8X9B Other fracture of unspecified femur, initial encounter for open fracture type I or II
• S72.8X9C Other fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC
• S72.90XA Unspecified fracture of unspecified femur, initial encounter for closed fracture
• S72.90XB Unspecified fracture of unspecified femur, initial encounter for open fracture type I or II
• S72.90XC Unspecified fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC
• S72.91XA Unspecified fracture of right femur, initial encounter for closed fracture
• S72.91XB Unspecified fracture of right femur, initial encounter for open fracture type I or II
• S72.91XC Unspecified fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC
• S72.92XA Unspecified fracture of left femur, initial encounter for closed fracture
• S72.92XB Unspecified fracture of left femur, initial encounter for open fracture type I or II
• S72.92XC Unspecified fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC
• S79.001A Unspecified physeal fracture of upper end of right femur, initial encounter for closed fracture
• S79.002A Unspecified physeal fracture of upper end of left femur, initial encounter for closed fracture
• S79.009A Unspecified physeal fracture of upper end of unspecified femur, initial encounter for closed fracture
• S79.011A Salter-Harris Type I physeal fracture of upper end of right femur, initial encounter for closed fracture
• S79.012A Salter-Harris Type I physeal fracture of upper end of left femur, initial encounter for closed fracture
• S79.019A Salter-Harris Type I physeal fracture of upper end of unspecified femur, initial encounter for closed fracture
• S79.091A Other physeal fracture of upper end of right femur, initial encounter for closed fracture
• S79.092A Other physeal fracture of upper end of left femur, initial encounter for closed fracture
• S79.099A Other physeal fracture of upper end of unspecified femur, initial encounter for closed fracture
• T36.0X5A Adverse effect of penicillins, initial encounter
• T36.1X5A Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter
• T36.2X5A Adverse effect of chloramphenicol group, initial encounter
• T36.3X5A Adverse effect of macrolides, initial encounter
• T36.4X5A Adverse effect of tetracyclines, initial encounter
• T36.5X5A Adverse effect of aminoglycosides, initial encounter
• T36.6X5A Adverse effect of rifampicins, initial encounter
• T36.7X5A Adverse effect of antifungal antibiotics, systemically used, initial encounter
• T36.8X5A Adverse effect of other systemic antibiotics, initial encounter
• T36.95XA Adverse effect of unspecified systemic antibiotic, initial encounter
• T37.0X5A Adverse effect of sulfonamides, initial encounter
• T37.1X5A Adverse effect of antimycobacterial drugs, initial encounter
• T37.2X5A Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter
• T37.3X5A Adverse effect of other antiprotozoal drugs, initial encounter
• T37.4X5A Adverse effect of anthelminthics, initial encounter
• T37.5X5A Adverse effect of antiviral drugs, initial encounter
• T37.8X5A Adverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter
• T37.95XA Adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter
• T38.0X5A Adverse effect of glucocorticoids and synthetic analogues, initial encounter
• T38.1X5A Adverse effect of thyroid hormones and substitutes, initial encounter
• T38.2X5A Adverse effect of antithyroid drugs, initial encounter
• T38.3X5A Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter
• T38.4X5A Adverse effect of oral contraceptives, initial encounter
• T38.5X5A Adverse effect of other estrogens and progestogens, initial encounter
• T38.6X5A Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter
• T38.7X5A Adverse effect of androgens and anabolic congeners, initial encounter
• T38.805A Adverse effect of unspecified hormones and synthetic substitutes, initial encounter
• T38.815A Adverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounter
• T38.895A Adverse effect of other hormones and synthetic substitutes, initial encounter
• T38.905A Adverse effect of unspecified hormone antagonists, initial encounter
• T38.995A Adverse effect of other hormone antagonists, initial encounter
• T39.015A Adverse effect of aspirin, initial encounter
• T39.095A Adverse effect of salicylates, initial encounter
• T39.1X5A Adverse effect of 4-Aminophenol derivatives, initial encounter
• T39.2X5A Adverse effect of pyrazolone derivatives, initial encounter
• T39.315A Adverse effect of propionic acid derivatives, initial encounter
• T39.395A Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
• T39.4X5A Adverse effect of antirheumatics, not elsewhere classified, initial encounter
• T39.8X5A Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter
• T39.95XA Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, initial encounter
• T40.0X5A Adverse effect of opium, initial encounter
• T40.2X5A Adverse effect of other opioids, initial encounter
• T40.3X5A Adverse effect of methadone, initial encounter
• T40.415A Adverse effect of fentanyl or fentanyl analogs, initial encounter
• T40.425A Adverse effect of tramadol, initial encounter
• T40.495A Adverse effect of other synthetic narcotics, initial encounter
• T40.5X5A Adverse effect of cocaine, initial encounter
• T40.605A Adverse effect of unspecified narcotics, initial encounter
• T40.695A Adverse effect of other narcotics, initial encounter
• T40.715A Adverse effect of cannabis, initial encounter
• T40.725A Adverse effect of synthetic cannabinoids, initial encounter
• T40.905A Adverse effect of unspecified psychodysleptics [hallucinogens], initial encounter
• T40.995A Adverse effect of other psychodysleptics [hallucinogens], initial encounter
• T41.0X5A Adverse effect of inhaled anesthetics, initial encounter
• T41.1X5A Adverse effect of intravenous anesthetics, initial encounter
• T41.205A Adverse effect of unspecified general anesthetics, initial encounter
• T41.295A Adverse effect of other general anesthetics, initial encounter
• T41.3X5A Adverse effect of local anesthetics, initial encounter
• T41.45XA Adverse effect of unspecified anesthetic, initial encounter
• T41.5X5A Adverse effect of therapeutic gases, initial encounter
• T42.0X5A Adverse effect of hydantoin derivatives, initial encounter
• T42.1X5A Adverse effect of iminostilbenes, initial encounter
• T42.2X5A Adverse effect of succinimides and oxazolidinediones, initial encounter
• T42.3X5A Adverse effect of barbiturates, initial encounter